Intellia Therapeutics Halts Late-Stage CRISPR Trials Following Patient Safety Issue

Intellia Therapeutics has announced a pause in two of its advanced CRISPR gene-editing clinical trials after a patient involved in one trial experienced liver damage that required hospitalization.